OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Rheumatology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
COVID-19 and autoimmune diseases	356
The role of diet in hyperuricemia and gout	69
Recent advances in targeted drug delivery for treatment of osteoarthritis	59
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate	59
Racial, ethnic, and healthcare disparities in rheumatoid arthritis	51
The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update	45
Double-negative T cells in autoimmune diseases	45
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications	45
Osteoporosis and fractures in rheumatoid arthritis	43
The association of Behçet's syndrome with HLA-B51 as understood in 2021	39
COVID-19 and rheumatoid arthritis	35
Inflammation in osteoarthritis: the latest progress and ongoing challenges	35
Telerheumatology: before, during, and after a global pandemic	33
Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers	33
Cellular aspects of the pathogenesis of lupus nephritis	33
Treatment for systemic sclerosis-associated interstitial lung disease	30
Interstitial lung disease throughout the rheumatoid arthritis disease course	30
Role of adipose tissues in osteoarthritis	26
Scleroderma epidemiology update	25
Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy	24
Update on gout management: what is old and what is new	23
Lymphocyte immunophenotyping in inflammatory myositis: a review	23
Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis	23
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	21
Update in familial Mediterranean fever	20

B cells in systemic lupus erythematosus	20
Insights into the molecular landscape of osteoarthritis in human tissues	19
Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit	19
Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells	18
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights	18
Posttraumatic osteoarthritis: what have we learned to advance osteoarthritis?	17
Ribosome dysfunction in osteoarthritis	17
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	17
An update on autoantibodies in systemic lupus erythematosus	16
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment	16
Calcinosis in systemic sclerosis	16
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis	15
Therapeutic advances in eosinophilic granulomatosis with polyangiitis	14
Low-dose computed tomography for axial spondyloarthritis: update on use and limitations	14
Janus kinase–signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition	14
Diagnostic delay in axial spondyloarthritis – a past or current problem?	14
Advances in osteoarthritis imaging	14
Polymyositis: does it really exist as a distinct clinical subset?	14
Takayasu arteritis	13
Differential diagnosis of necrotizing myopathy	13
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance	13
Is osteoarthritis a mitochondrial disease? What is the evidence	12
Update on the cellular pathogenesis of lupus	12
Did COVID-19 impact osteoarthritis – clinical perspective?	12
The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy	12
Role of cellular senescence in the pathogenesis of systemic sclerosis	12
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach	12
Review of publications evaluating opioid use in patients with inflammatory rheumatic disease	12
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	11
Scleroderma autoantibodies in guiding monitoring and treatment decisions	11
Gout and the COVID-19 pandemic	11
Fibromyalgia and centralized pain in the rheumatoid arthritis patient	11
A cursed goodbye kiss from severe acute respiratory syndrome-coronavirus-2 to its pediatric hosts: multisystem inflammatory syndrome in children	11
The transition from enthesis physiological responses in health to aberrant responses that underpin spondyloarthritis mechanisms	11
Glucocorticoid and opioid use in rheumatoid arthritis management	11
Integrating genetic and social factors to understand health disparities in lupus	10
New lupus criteria: a critical view	10
Raynaud's phenomenon and digital ulcers: advances in evaluation and management	10
Immunopathogenesis of skin injury in systemic lupus erythematosus	10
Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus	10
Intestinal dysbiosis in spondyloarthritis – chicken or egg?	9
Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence	9
Uveitis in Behçet disease - an update	9
Haematopoietic stem cell transplantation in paediatric rheumatic disease	9
Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus	9
Role of Janus Kinase inhibitors in rheumatoid arthritis treatment	9
Current views on lupus in children	9